{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:31:01Z","timestamp":1787740261548,"version":"build-2784847793"},"reference-count":87,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amicus Therapeutics, Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The treatment landscape for lysosomal storage disorders (LSDs) is rapidly evolving. An increase in the number of preclinical and clinical studies in the last decade has demonstrated that pharmacological chaperones are a feasible alternative to enzyme replacement therapy (ERT) for individuals with LSDs. A systematic search was performed to retrieve and critically assess the evidence from preclinical and clinical applications of pharmacological chaperones in the treatment of LSDs and to elucidate the mechanisms by which they could be effective in clinical practice. Publications were screened according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) reporting guidelines. Fifty-two articles evaluating 12 small molecules for the treatment of seven LSDs are included in this review. Overall, a substantial amount of preclinical and clinical data support the potential of pharmacological chaperones as treatments for Fabry disease, Gaucher disease, and Pompe disease. Most of the available clinical evidence evaluated migalastat for the treatment of Fabry disease. There was a lack of consistency in the terminology used to describe pharmacological chaperones in the literature. Therefore, the new small molecule chaperone (SMC) classification system is proposed to inform a standardized approach for new, emerging small molecule therapies in LSDs.<\/jats:p>","DOI":"10.3390\/biom13081227","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T06:37:31Z","timestamp":1691390251000},"page":"1227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification"],"prefix":"10.3390","volume":"13","author":[{"given":"Ian","family":"Keyzor","sequence":"first","affiliation":[{"name":"Amicus Therapeutics Ltd., Marlow SL7 1HZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Shohet","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Ltd., Marlow SL7 1HZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Castelli","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Inc., Princeton, NJ 08542, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Sitaraman","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Inc., Princeton, NJ 08542, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-0112","authenticated-orcid":false,"given":"Biliana","family":"Veleva-Rotse","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Inc., Princeton, NJ 08542, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Weimer","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Inc., Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Fox","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Inc., Princeton, NJ 08542, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Willer","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Inc., Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Tuske","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Inc., Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Crathorne","sequence":"additional","affiliation":[{"name":"Prescript Communications Ltd., Letchworth Garden City SG6 3TA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara J.","family":"Belzar","sequence":"additional","affiliation":[{"name":"Prescript Communications Ltd., Letchworth Garden City SG6 3TA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/EBC20160005","article-title":"Cellular proteostasis: Degradation of misfolded proteins by lysosomes","volume":"60","author":"Jackson","year":"2016","journal-title":"Essays Biochem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim. Biophys. Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100926","DOI":"10.1016\/j.ymgmr.2022.100926","article-title":"\u03b1-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response","volume":"33","author":"Consolato","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPH.0000000000002506","article-title":"Global epidemiology of Gaucher disease: An updated systematic review and meta-analysis","volume":"45","author":"Wang","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cytogfr.2018.04.003","article-title":"Molecular regulations and therapeutic targets of Gaucher disease","volume":"41","author":"Chen","year":"2018","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease\u2014Current treatment and new drug development","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genom."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Meena, N.K., and Raben, N. (2020). Pompe disease: New developments in an old lysosomal storage disorder. Biomolecules, 10.","DOI":"10.3390\/biom10091339"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/jimd.12428","article-title":"Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2\/3 trial of a novel treatment","volume":"44","author":"Mengel","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Garbade, S.F., Zielonka, M., Mechler, K., K\u00f6lker, S., Hoffmann, G.F., Staufner, C., Mengel, E., and Ries, M. (2020). FDA orphan drug designations for lysosomal storage disorders\u2014A cross-sectional analysis. PLoS ONE, 15.","DOI":"10.1101\/2020.01.05.20016568"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Ann. Rev. Genom. Hum. Genet."},{"key":"ref_11","unstructured":"(2023, May 30). European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: The Current Treatment Landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: Efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Italian J. Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: Preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological enhancement of \u03b1-glucosidase by the allosteric chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"Valenzano","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.04.002","article-title":"Using pharmacological chaperones to restore proteostasis","volume":"83","author":"Wang","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A chaperone enhances blood \u03b1-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): An international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_23","unstructured":"Selvan, N., Venkateswaran, S., Feng, J., Madrid, M., Mehta, N., and Graziano, M. (2021, January 15\u201318). Enhancing delivery of acid alpha-glucosidae (GAA) to skeletal muscle in Pompe disease (PD): Key challenges and attributes of AT-GAA. Proceedings of the Poster presented at the virtual Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, Dallas, TX, USA. Poster No. 11."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e125358","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.omtm.2020.05.026","article-title":"Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease","volume":"18","author":"Meena","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40265-023-01886-5","article-title":"Cipaglucosidase alfa: First approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tedesco, B., Ferrari, V., Cozzi, M., Chierichetti, M., Casarotto, E., Pramaggiore, P., Mina, F., Galbiati, M., Rusmini, P., and Crippa, V. (2022). The role of small heat shock proteins in protein misfolding associated motoneuron diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911759"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2174\/1568026611212220014","article-title":"Protein homeostasis as a therapeutic target for diseases of protein conformation","volume":"12","author":"Calamini","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ajh.26276","article-title":"Clinical outcomes after 4.5\u2009years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results","volume":"96","author":"Mistry","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher\u2019s disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: Real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year","volume":"105","author":"Gensler","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of fabry\u2019s disease with migalastat: Outcome from a prospective observational multicenter study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2021","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1002\/mgg3.894","article-title":"Strong increase of leukocyte apha-galactosidase A activity in two male patients with Fabry disease following oral chaperone therapy","volume":"7","author":"Lamari","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","article-title":"A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects","volume":"109","author":"Giugliani","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: Data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100786","DOI":"10.1016\/j.ymgmr.2021.100786","article-title":"Long-term follow-up of renal function in patients treated with migalastat for Fabry disease","volume":"28","author":"Bichet","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Hughes","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_42","unstructured":"PRISMA (2023, June 30). Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Available online: http:\/\/www.prisma-statement.org\/."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106981","DOI":"10.1016\/j.ymgme.2022.106981","article-title":"Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study","volume":"138","author":"Lau","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_45","first-page":"ehab724.1744","article-title":"Effect of Migalastat on cArdiac Involvement in FabRry Disease: MAIORA study","volume":"42","author":"Camporeale","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1006\/bbrc.1995.2416","article-title":"Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease","volume":"214","author":"Okumiya","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1750-1172-6-66","article-title":"Therapy of Fabry disease with pharmacological chaperones: From in silico predictions to in vitro tests","volume":"6","author":"Andreotti","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lukas, J., Giese, A.K., Markoff, A., Grittner, U., Kolodny, E., Mascher, H., Lackner, K.J., Meyer, W., Wree, P., and Saviouk, V. (2013). Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003632"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lukas, J., Cimmaruta, C., Liguori, L., Pantoom, S., Iwanov, K., Petters, J., Hund, C., Bunschkowski, M., Hermann, A., and Cubellis, M.V. (2020). Assessment of gene variant amenability for pharmacological chaperone therapy with 1-deoxygalactonojirimycin in Fabry disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030956"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/BCJ20190513","article-title":"Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease","volume":"477","author":"Seemann","year":"2020","journal-title":"Biochem. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s10038-008-0316-9","article-title":"Structural characterization of mutant alpha-galactosidases causing Fabry disease","volume":"53","author":"Sugawara","year":"2008","journal-title":"J. Hum. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum. Mutat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human \u03b1-galactosidase a: Pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"907317","DOI":"10.3389\/fneur.2022.907317","article-title":"Promising Effect of High Dose Ambroxol Treatment on Neurocognition and Motor Development in a Patient With Neuropathic Gaucher Disease 2","volume":"13","author":"Aries","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_61","first-page":"7031","article-title":"Neuronopathic Gaucher disease: Dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model","volume":"24","author":"Dasgupta","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid \u03b2-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Sun","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Mena-Barrag\u00e1n, T., Garc\u00eda-Moreno, M.I., Sev\u0161ek, A., Okazaki, T., Nanba, E., Higaki, K., Martin, N.I., Pieters, R.J., Fern\u00e1ndez, J.M.G., and Mellet, C.O. (2018). Probing the inhibitor versus chaperone properties of sp2-Iminosugars towards human \u03b2-glucocerebrosidase: A picomolar chaperone for Gaucher disease. Molecules, 23.","DOI":"10.3390\/molecules23040927"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ebiom.2018.11.037","article-title":"The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase","volume":"38","author":"Fog","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta-glucosidase: A therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/cb600187q","article-title":"Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants","volume":"1","author":"Sawkar","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Maor","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces \u03b1-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","article-title":"Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II","volume":"90","author":"Okumiya","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ana.21284","article-title":"Chemical chaperone therapy: Clinical effect in murine G(M1)-gangliosidosis","volume":"62","author":"Suzuki","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","article-title":"An open-label Phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)","volume":"102","author":"Clarke","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13023-015-0260-7","article-title":"Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: An open label, extended pilot study","volume":"10","author":"Osher","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","article-title":"Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis","volume":"282","author":"Maegawa","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1039\/C7CC09642A","article-title":"A combinatorial approach towards the synthesis of non-hydrolysable triazole-iduronic acid hybrid inhibitors of human \u03b1-l-iduronidase: Discovery of enzyme stabilizers for the potential treatment of MPSI","volume":"54","author":"Cheng","year":"2018","journal-title":"Chem. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","article-title":"Miglustat for treatment of Niemann-Pick C disease: A randomised controlled study","volume":"6","author":"Patterson","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of Fabry and Pompe disease","volume":"23","author":"Lukas","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Pantoom, S., Hules, L., Sch\u00f6ll, C., Petrosyan, A., Monticelli, M., Pospech, J., Cubellis, M.V., Hermann, A., and Lukas, J. (2022). Mechanistic insight into the mode of action of acid \u03b2-glucosidase enhancer ambroxol. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073536"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"100678","DOI":"10.1016\/j.ymgmr.2020.100678","article-title":"In vitro and in vivo effects of ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy","volume":"25","author":"Ciana","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/mp200313e","article-title":"Therapeutic strategies for Gaucher disease: Miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerasealfa and imiglucerase","volume":"8","author":"Abian","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Liguori, L., Monticelli, M., Allocca, M., Mele, B.H., Lukas, J., Cubellis, M.V., and Andreotti, G. (2020). Pharmacological chaperones: A therapeutic approach for diseases caused by destabilizing missense mutations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020489"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-126-5-199703010-00006","article-title":"Systematic reviews: Synthesis of best evidence for clinical decisions","volume":"126","author":"Cook","year":"1997","journal-title":"Ann. Intern. Med."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/8\/1227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:27:18Z","timestamp":1760128038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/8\/1227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":87,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["biom13081227"],"URL":"https:\/\/doi.org\/10.3390\/biom13081227","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]}}}